Inhibition of a Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Activity by Peptidylarginine Deiminase IV Exacerbates Pancreatic Necrosis in Acute Pancreatitis Authors: Wenjian Mao, Yiting Guan, Zongwen Zhang, Jing Zhou, Bo Ye, Gang Li, Jingzhu Zhang, Qi Yang, Shuang Peng, Wangsen Cao, Lin Gao, Weiqin Li, Lu Ke Published: 2026 ABSTRACT Background & AimsDysregulation of the von Willebrand factor and its protease, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13, has been implicated in the pathogenesis of pancreatic necrosis during acute pancreatitis, but the underlying mechanisms remain incompletely understood. NETosis and their enzyme component, peptidylarginine deiminase type IV, have been proposed to inhibit a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13. We aimed to determine whether peptidylarginine deiminase type IV–mediated inhibition of a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 contributes to the progression of pancreatic injury in acute pancreatitis.MethodsSerum a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity and peptidylarginine deiminase type IV levels were prospectively assessed in 30 patients with acute pancreatitis. Peptidylarginine deiminase type IV–a disintegrin and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 interactions were examined in vitro and in vivo. Experimental acute pancreatitis was induced in mice using cerulein plus lipopolysaccharide or L-arginine, with interventions including recombinant human a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13, the peptidylarginine deiminase type IV inhibitor Cl-amidine, and genetic knockout models (Pad4−/− and Adamts13−/−).ResultsPatients with acute pancreatitis and >30% pancreatic necrosis exhibited significantly reduced a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity, elevated peptidylarginine deiminase type IV levels, and accumulation of large von Willebrand factor multimers. In mouse acute pancreatitis models, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 deficiency worsened pancreatic necrosis and systemic injury, whereas recombinant human a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 treatment conferred protection. Mechanistically, peptidylarginine deiminase type IV suppressed a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity both in vitro and in vivo; this inhibition was reversed by Cl-amidine. Peptidylarginine deiminase type IV inhibition attenuated acute pancreatitis severity, but this effect was abolished in Adamts13−/− mice, demonstrating that peptidylarginine deiminase type IV aggravates acute pancreatitis primarily through a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 suppression.ConclusionsAn early imbalance in the von Willebrand factor–a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 axis and peptidylarginine deiminase type IV activation is a hallmark of both clinical and experimental acute pancreatitis. By inhibiting a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity, peptidylarginine deiminase type IV promotes pancreatic necrosis and exacerbates disease severity. Targeting peptidylarginine deiminase type IV or restoring a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity may represent a promising therapeutic strategy to protect against pancreatic injury in acute pancreatitis. SummaryInflammation, thrombosis, and their interaction play crucial roles in the pathogenesis of pancreatic necrosis. Peptidylarginine deiminase type IV inhibited a disintegrin and metalloproteinase with thrombospondin motifs 13 both in vitro and in vivo, playing a deleterious role in acute pancreatitis. What You Need to KnowBackgroundInflammation, thrombosis, and their interaction play crucial roles in the pathogenesis of pancreatic necrosis, but the crosstalk between neutrophil–extracellular trap components and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13/von Willebrand factor in acute pancreatitis remains largely unexplored.ImpactPeptidylarginine deiminase type IV, a key component of neutrophil–extracellular traps, inhibited a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity both in vitro and in vivo, playing a deleterious role in acute pancreatitis.Future DirectionsTherapies aimed at restoring or enhancing a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity, potentially in combination with peptidylarginine deiminase type IV inhibition, may hold significant promise for treating acute pancreatitis and other thrombo-inflammatory disorders. Summary Inflammation, thrombosis, and their interaction play crucial roles in the pathogenesis of pancreatic necrosis. Peptidylarginine deiminase type IV inhibited a disintegrin and metalloproteinase with thrombospondin motifs 13 both in vitro and in vivo, playing a deleterious role in acute pancreatitis. What You Need to Know Background Inflammation, thrombosis, and their interaction play crucial roles in the pathogenesis of pancreatic necrosis, but the crosstalk between neutrophil–extracellular trap components and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13/von Willebrand factor in acute pancreatitis remains largely unexplored. Impact Peptidylarginine deiminase type IV, a key component of neutrophil–extracellular traps, inhibited a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity both in vitro and in vivo, playing a deleterious role in acute pancreatitis. Future Directions Therapies aimed at restoring or enhancing a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity, potentially in combination with peptidylarginine deiminase type IV inhibition, may hold significant promise for treating acute pancreatitis and other thrombo-inflammatory disorders. Acute pancreatitis (AP) is an inflammatory disorder with substantial morbidity and mortality. Approximately 20% of patients develop severe AP, marked by persistent organ failure, pancreatic necrosis, and other local or systemic complications.1 The limited understanding of pancreatic necrosis pathogenesis constrains therapies to supportive care and, when needed, invasive interventions. Pancreatic microcirculatory disturbance arises early in AP and is closely related to the development of pancreatic necrosis.2, 3, 4, 5 Given the acute inflammatory nature of AP, immunothrombosis—the interface of inflammation and thrombosis, which can impair perfusion and induce tissue ischemia—may play a crucial role in the pathogenesis of pancreatic necrosis.6 A recent prospective cohort study revealed early imbalance in the von Willebrand Factor (VWF) and its protease—a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13)—that correlated with the extent of pancreatic necrosis.7 Functionally, VWF promotes thrombosis by capturing platelets at sites of vascular injury, particularly in its ultra-large form.8,9 ADAMTS13 cleaves ultra-large–VWF into smaller, less thrombogenic fragments, and reduced ADAMTS13 activity has been implicated in various thrombo-inflammatory diseases.10, 11, 12 In ischemic diseases, recombinant human (rh) ADAMTS13 has shown efficacy in preventing microthrombosis and dampening inflammation.13,14 However, the mechanisms driving VWF–ADAMTS13 imbalance in AP are not yet understood. Emerging evidence implicates neutrophils and neutrophil–extracellular traps (NETs) in AP.15,16 Peptidylarginine deiminase type IV (PAD4), a key mediator of NETosis, can inactivate ADAMTS13 via citrullination, thereby promoting VWF–platelet string formation and thrombosis.17 Given the prothrombotic and proinflammatory nature of both NETs and the VWF–ADAMTS13 imbalance, their interaction may serve as a novel therapeutic target in AP. This study aimed to investigate the clinical relevance of VWF–ADAMTS13 axis and its regulation by PAD4 in patients with AP and mouse models. The role of ADAMTS13 was assessed using rhADAMTS13 and Adadmts13 knockout (Adamts13−/−) mice, whereas the effects of PAD4 were evaluated through genetic deletion and pharmacologic inhibition. Results Plasma A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Activity Negatively Correlates With Peptidylarginine Deiminase Type IV Levels in Patients With Acute Pancreatitis In a prospective cohort of 30 patients with AP, those with >30% pancreatic necrosis (n = 12) exhibited significantly lower ADAMTS13 activity and higher levels of large molecular–size VWF polymers, plasma PAD4, and cell-free DNA (cfDNA) compared with those with ≤30% necrosis (n = 18) (Figure 1A and B). In addition, dynamic trend analyses showed that patients with >30% pancreatic necrosis consistently exhibited higher levels of large molecular–size VWF polymers, plasma PAD4, and cfDNA, as well as lower ADAMTS13 activity during the first 3 days after enrollment (Figures 2 and 3). Furthermore, receiver operating characteristic (ROC) analysis demonstrated that ADAMTS13 activity at enrollment and cfDNA levels had superior predictive value for extensive pancreatic necrosis (>30%) compared with the Acute Physiology and Chronic Health Evaluation II score, with areas under the ROC curves of 0.82, 0.76, and 0.75, respectively (Figure 1C). Correlation analyses showed that PAD4 and cfDNA levels were strongly negatively correlated with ADAMTS13 activity (P = .029 and P < .001, respectively) (Figure 1D). Conversely, PAD4 and cfDNA levels were both significantly positively correlated with VWF relative expression (both P < .001) (Figure 1E).Figure 1Plasma PAD4 levels negatively correlate with ADAMTS13 activity in patients with AP. (A) Study flow chart. (B) Plasma levels of key NET components (including cfDNA, citH3-DNA, MPO-DNA, PAD4), ADAMTS13 activity, and relative expression at enrollment in the 2 groups. ADAMTS13 activity was evaluated based on its ability to cleave FRETS-VWF73, with activity from healthy controls set at 100% and used as the reference for normalization. (C) ROC curves of various markers for predicting pancreatic necrosis (PN) >30%. (D) Correlations between ADAMTS13 activity and individual NET components. (E) Correlations between VWF relative expression and individual NET components. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.Figure 2The distribution of large molecular size VWF polymers in plasma over the first 3 days after enrollment of patients with PN area ≤ 30% (A) or >30% (B). PN, pancreatic necrosis.Figure 3Dynamic changes in plasma ADAMTS13 activity (A), VWF relative expression (B), cfDNA (C), and PAD4 (D) during the first 3 days after enrollment. ADAMTS13 activity was evaluated based on its ability to cleave FRETS-VWF73, with activity from healthy controls set at 100% and used as the reference for normalization. “Mean difference” represents the average difference between the 2 groups across the 3-day period. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PN, pancreatic necrosis. Plasma PAD4 levels negatively correlate with ADAMTS13 activity in patients with AP. (A) Study flow chart. (B) Plasma levels of key NET components (including cfDNA, citH3-DNA, MPO-DNA, PAD4), ADAMTS13 activity, and relative expression at enrollment in the 2 groups. ADAMTS13 activity was evaluated based on its ability to cleave FRETS-VWF73, with activity from healthy controls set at 100% and used as the reference for normalization. (C) ROC curves of various markers for predicting pancreatic necrosis (PN) >30%. (D) Correlations between ADAMTS13 activity and individual NET components. (E) Correlations between VWF relative expression and individual NET components. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. The distribution of large molecular size VWF polymers in plasma over the first 3 days after enrollment of patients with PN area ≤ 30% (A) or >30% (B). PN, pancreatic necrosis. Dynamic changes in plasma ADAMTS13 activity (A), VWF relative expression (B), cfDNA (C), and PAD4 (D) during the first 3 days after enrollment. ADAMTS13 activity was evaluated based on its ability to cleave FRETS-VWF73, with activity from healthy controls set at 100% and used as the reference for normalization. “Mean difference” represents the average difference between the 2 groups across the 3-day period. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PN, pancreatic necrosis. The Protective Role of A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 in Severe Acute Pancreatitis in Mice RhADAMTS13 was administered at 10, 50, and 250 μg/kg to assess its therapeutic effect in the caerulein (CER) + lipopolysaccharide (LPS)–induced severe acute pancreatitis (SAP) mouse model. rhADAMTS13 mitigated pancreatic injury in a dose-dependent manner, as reflected by significantly reduced pancreatic necrosis and serum amylase levels (Figure 4A–D). Western blot showed decreased plasma ADAMTS13 in SAP, which was restored to near-control levels with high-dose rhADAMTS13 (Figure 4E). SAP mice exhibited elevated large molecular–size VWF polymers, which were reduced by rhADAMTS13 administration (Figure 4F). Furthermore, rhADAMTS13 also attenuated pancreatic thrombosis (immunohistochemistry staining of fibrinogen), VWF-platelet string formation (immunofluorescence staining of VWF and platelet surface glycoprotein CD41), and plasma levels of endothelial injury markers endothelial protein C receptor (EPCR) and P-selectin (Figure 4G and H). We also compared the effect of rhADAMTS13 drug administration at 0, 1, and 3 hours postinduction, and the data demonstrate a protective effect across all tested time points, with the most robust benefit observed when treatment was initiated at the 1-hour mark (Figure 5).Figure 4RhADAMTS13 protects mice from SAP. (A) Study schematic: CER+LPS–induced SAP mice were injected with vehicle (PBS) or rhADAMTS13 (10, 50, or 250 μg/kg) immediately after the first CER dose. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Plasma amylase levels at 12 hours. (D) Histologic scores of pancreatic injury. (E) Western blotting of plasma ADAMTS13. (F) The distribution of large molecular–size VWF polymers in plasma. (G) Immunohistochemistry staining for fibrinogen (as a marker of thrombosis) and immunofluorescence staining for VWF and the platelet surface glycoprotein CD41 (indicating VWF–platelet string formation) in pancreatic tissue. Scale bar, 50 μm. (H) Plasma EPCR and P-selectin levels. Data are expressed as mean ± standard error of the mean, n = 6 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.Figure 5The effect of rhADAMTS13 on SAP mice at different timepoints. (A) Study schematic: CER+LPS–induced SAP mice were injected with vehicle (PBS) or rhADAMTS13 (0, 1, or 3 hours after the first CER dose). Mice were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Plasma amylase levels at 12 hours. (D) Histologic scores of pancreatic injury. Data are expressed as mean ± standard error of the mean, n = 6 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. RhADAMTS13 protects mice from SAP. (A) Study schematic: CER+LPS–induced SAP mice were injected with vehicle (PBS) or rhADAMTS13 (10, 50, or 250 μg/kg) immediately after the first CER dose. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Plasma amylase levels at 12 hours. (D) Histologic scores of pancreatic injury. (E) Western blotting of plasma ADAMTS13. (F) The distribution of large molecular–size VWF polymers in plasma. (G) Immunohistochemistry staining for fibrinogen (as a marker of thrombosis) and immunofluorescence staining for VWF and the platelet surface glycoprotein CD41 (indicating VWF–platelet string formation) in pancreatic tissue. Scale bar, 50 μm. (H) Plasma EPCR and P-selectin levels. Data are expressed as mean ± standard error of the mean, n = 6 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. The effect of rhADAMTS13 on SAP mice at different timepoints. (A) Study schematic: CER+LPS–induced SAP mice were injected with vehicle (PBS) or rhADAMTS13 (0, 1, or 3 hours after the first CER dose). Mice were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Plasma amylase levels at 12 hours. (D) Histologic scores of pancreatic injury. Data are expressed as mean ± standard error of the mean, n = 6 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. Conversely, Adamts13 knockout (Adamts13−/−) mice exhibited worsened pancreatic injury and distant organ damage, as evidenced by increased pancreatic necrosis, severity of acute lung injury, and serum amylase levels in CER+LPS–induced SAP (Figure 6A–C), along with increased VWF–platelet strings in the pancreas and large molecular–size VWF polymers in the plasma (Figure 6D–F). Similar aggravation was observed in L-arginine (ARG)-induced SAP (Figure 7A–E). Kaplan–Meier curves showed a significantly decreased survival rate in Adamts13−/− mice (log-rank P < .001) (Figure 7B).Figure 6ADAMTS13 knockout (Adamts13−/−) mice exhibits increased severity of SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Adamts13−/−) were harvested at 24 hours after the first CER injection. (A) Representative hematoxylin and eosin images of pancreas and lungs in CER+LPS–induced SAP model. Scale bar, 200 or 50 μm. n = 5 or 6 per group. (B) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 5 or 6 per group. (C) Histologic scores of lung injury. n = 5 or 6 per group. (D) Immunofluorescence staining for VWF and CD41 in pancreatic tissues. Scale bar, 50 μm. n = 5 or 6 per group. (E) Western blotting of plasma ADAMTS13. n = 5 or 6 per group. (F) The distribution of large molecular–size VWF polymers in plasma. n = 5 or 6 per group. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.Figure 7ADAMTS13 knockout (Adamts13−/−) mice exhibits increased severity of ARG-induced SAP. (A) Study schematic: WT or Adamts13−/− mice were injected with ARG to induce SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 72 hours after the first ARG injection. (B) Kaplan–Meier curve showing survival rates. n = 22 per group. (C) Representative hematoxylin and eosin images of pancreas in ARG-induced SAP model. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours. n = 9–16 per group. (E) Histologic score of pancreatic injury and cell death area of pancreas. n = 2–11 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. ADAMTS13 knockout (Adamts13−/−) mice exhibits increased severity of SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Adamts13−/−) were harvested at 24 hours after the first CER injection. (A) Representative hematoxylin and eosin images of pancreas and lungs in CER+LPS–induced SAP model. Scale bar, 200 or 50 μm. n = 5 or 6 per group. (B) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 5 or 6 per group. (C) Histologic scores of lung injury. n = 5 or 6 per group. (D) Immunofluorescence staining for VWF and CD41 in pancreatic tissues. Scale bar, 50 μm. n = 5 or 6 per group. (E) Western blotting of plasma ADAMTS13. n = 5 or 6 per group. (F) The distribution of large molecular–size VWF polymers in plasma. n = 5 or 6 per group. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. ADAMTS13 knockout (Adamts13−/−) mice exhibits increased severity of ARG-induced SAP. (A) Study schematic: WT or Adamts13−/− mice were injected with ARG to induce SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 72 hours after the first ARG injection. (B) Kaplan–Meier curve showing survival rates. n = 22 per group. (C) Representative hematoxylin and eosin images of pancreas in ARG-induced SAP model. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours. n = 9–16 per group. (E) Histologic score of pancreatic injury and cell death area of pancreas. n = 2–11 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. Peptidylarginine Deiminase Type IV Inhibits A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Activity In Vitro To explore the effects of PAD4 on ADAMTS13 activity, rhADAMTS13 was incubated with rhPAD4 in vitro for 3 hours, and then ADAMTS13 activity was then assessed by measuring its ability to cleave FRETS-VWF73 (Figure 8A). As shown in Figure 8B, compared with the control group with rhADAMTS13 alone, incubation with rhPAD4 significantly reduced ADAMTS13 activity (mean, 1.00 vs 0.21; P < .001). Notably, pretreatment of PAD4 with Cl-amidine—an irreversible PAD inhibitor—substantially preserved ADAMTS13 activity (mean, 0.21 vs 0.76; P < .001) (Figure 8C and D).Figure 8PAD4 inhibits ADAMTS13 activity in vitro. (A) Schematic of rhADAMTS13 and rhPAD4 coincubation: rhADAMTS13 was incubated with rhPAD4 for 3 hours, followed by assessment of ADAMTS13 activity by measuring its ability to cleave FRETS-VWF73. The fluorescence generated by the reaction between ADAMTS13 and FRETS-VWF73 was continuously recorded for 1 hour. ADAMTS13 activity was calculated by analyzing the slope value of the linear phase of the fluorescence curve. (B) Fluorescence curves showing FRETS-VWF73 cleavage in 3 conditions: rhADAMTS13 alone (positive control), rhPAD4 alone (negative control), and coincubation of rhADAMTS13 with rhPAD4. n = 4 per group (each linear line represents an individual sample). (C) Study schematic: Prior to coincubation of rhPAD4 with rhADAMTS13, rhPAD4 was preincubated with Cl-amidine (an irreversible PAD inhibitor) for 20 minutes to inhibit its activity. (D) Fluorescence curves showing FRETS-VWF73 cleavage under 3 conditions: Cl-amidine alone (negative control), coincubation of rhADAMTS13 with rhPAD4, and coincubation of rhADAMTS13 with rhPAD4 pretreated with Cl-amidine. n = 4 per group (each linear line represents an individual sample). Data are expressed as mean ± standard error of the mean, n = 4 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PAD4 inhibits ADAMTS13 activity in vitro. (A) Schematic of rhADAMTS13 and rhPAD4 coincubation: rhADAMTS13 was incubated with rhPAD4 for 3 hours, followed by assessment of ADAMTS13 activity by measuring its ability to cleave FRETS-VWF73. The fluorescence generated by the reaction between ADAMTS13 and FRETS-VWF73 was continuously recorded for 1 hour. ADAMTS13 activity was calculated by analyzing the slope value of the linear phase of the fluorescence curve. (B) Fluorescence curves showing FRETS-VWF73 cleavage in 3 conditions: rhADAMTS13 alone (positive control), rhPAD4 alone (negative control), and coincubation of rhADAMTS13 with rhPAD4. n = 4 per group (each linear line represents an individual sample). (C) Study schematic: Prior to coincubation of rhPAD4 with rhADAMTS13, rhPAD4 was preincubated with Cl-amidine (an irreversible PAD inhibitor) for 20 minutes to inhibit its activity. (D) Fluorescence curves showing FRETS-VWF73 cleavage under 3 conditions: Cl-amidine alone (negative control), coincubation of rhADAMTS13 with rhPAD4, and coincubation of rhADAMTS13 with rhPAD4 pretreated with Cl-amidine. n = 4 per group (each linear line represents an individual sample). Data are expressed as mean ± standard error of the mean, n = 4 per group. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. Peptidylarginine Deiminase Type IV Aggravates Severe Acute Pancreatitis and Inhibits A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Activity by Citrullination Administration of rhPAD4 (10 mg/kg) significantly exacerbated pancreatic injury, endothelial damage, and systemic inflammation in CER+LPS–induced SAP mice, as evidenced by increased pancreatic necrosis, serum amylase, EPCR, and interleukin6 levels (Figure 9A and B). The immunohistochemistry staining confirmed elevated PAD4 expression, and immunofluorescence staining showed increased citrullinated histone H3 (CitH3)/myeloperoxidase (MPO) colocalization in pancreatic tissues (Figure 9C). rhPAD4 significantly reduced ADAMTS13 activity (Figure 9D) and increased large molecular–size VWF polymers accumulation detected by vertical electrophoresis (Figure 9E). Conversely, PAD4 inhibition with Cl-amidine (5 mg/kg) alleviated pancreatic and endothelial injury and systemic inflammation (Figure 10A and B). Similarly, Cl-amidine reduced PAD4 expression and CitH3/MPO costaining in pancreatic tissue (Figure 10C), preserved ADAMTS13 activity (Figure 10D), and decreased the formation of large molecular–size VWF polymers in the plasma (Figure 10E).Figure 9PAD4 aggravates SAP in mice. In the intervention group, mice received a single intraperitoneal injection of recombinant PAD4 (10 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images, plasma amylase levels at 12 hours, histologic scores of pancreatic injury, and cell death area of pancreas. Scale bar, 200 or 50 μm. n = 5–6 per group. (B) Plasma levels of EPCR, P-selectin, and inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin6 [IL6]). n = 5–6 per group. (C) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 5-6 per group. (D) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 5–6 per group. (E) The distribution of large molecular–size VWF polymers in plasma. n = 5–6 per group. Data are expressed as mean ± standard error of the mean. Ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.Figure 10PAD4 inhibitor protects mice from SAP. In the intervention group, mice received a single intraperitoneal injection of Cl-amidine (5 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images, plasma amylase levels at 12 hours, histologic scores of pancreatic injury, and cell death area of pancreas. Scale bar, 200 or 50 μm. n = 6 per group. (B) plasma levels of EPCR, P-selectin, and inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin6 [IL6]). n = 6 per group. (C) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 6 per group. (D) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 6 per group. (E) The distribution of large molecular–size VWF polymers in plasma. n = 6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PAD4 aggravates SAP in mice. In the intervention group, mice received a single intraperitoneal injection of recombinant PAD4 (10 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images, plasma amylase levels at 12 hours, histologic scores of pancreatic injury, and cell death area of pancreas. Scale bar, 200 or 50 μm. n = 5–6 per group. (B) Plasma levels of EPCR, P-selectin, and inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin6 [IL6]). n = 5–6 per group. (C) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 5-6 per group. (D) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 5–6 per group. (E) The distribution of large molecular–size VWF polymers in plasma. n = 5–6 per group. Data are expressed as mean ± standard error of the mean. Ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PAD4 inhibitor protects mice from SAP. In the intervention group, mice received a single intraperitoneal injection of Cl-amidine (5 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images, plasma amylase levels at 12 hours, histologic scores of pancreatic injury, and cell death area of pancreas. Scale bar, 200 or 50 μm. n = 6 per group. (B) plasma levels of EPCR, P-selectin, and inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin6 [IL6]). n = 6 per group. (C) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 6 per group. (D) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 6 per group. (E) The distribution of large molecular–size VWF polymers in plasma. n = 6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. To address potential off-target effects of the PAD4 inhibitor, Pad4 knockout (Pad4−/−) mice were used to validate the findings. Compared with wild-type (WT) littermates, Pad4−/− mice with CER+LPS–induced SAP exhibited significantly reduced pancreatic necrosis, lung injury, serum amylase, PAD4 expression, and NETs formation, along with increased ADAMTS13 activity (Figure 11A–G). Similar protective effects were observed in the ARG-induced SAP model (Figure 12A–E). Survival was significantly improved in Pad4−/− mice (log-rank P = .032) (Figure 12B). To investigate PAD4-mediated citrullination of ADAMTS13, plasma from Pad4−/− and WT SAP mice was analyzed by immunoprecipitation and Western blotting. A 190 kDa citrullinated ADAMTS13 band was detected in WT-SAP mice but absent in Pad4−/− mice (Figure 11H), confirming PAD4-dependent citrullination of ADAMTS13 in SAP.Figure 11PAD4 knockout alleviates SAP and inhibits ADAMTS13 activity by citrullination. Details for experimental SAP induction and severity assessment are described in Materials and Methods section. Mice (WT and Pad4−/−) were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images of pancreas and lungs in CER+LPS–induced SAP model. Scale bar, 200 or 50 μm. n = 6 per group. (B) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 6 per group. (C) Histologic scores of lung injuries. n = 6 per group. (D) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 6 per group. (E) Western blotting of PAD4 in pancreatic tissue. n = 6 per group. (F) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 6 per group. (G) The distribution of large molecular–size VWF polymers in plasma. n = 6 per group. (H) Citrullinated ADAMTS13 detected by immunoprecipitation. n = 6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.Figure 12PAD4 knockout (Pad4−/−) mice exhibits increased severity of ARG-induced SAP. (A) Study schematic: WT or Pad4−/− mice were injected with ARG to induce SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Pad4−/−) were harvested at 72 hours after the first ARG injection. (B) Kaplan–Meier curve showing survival rates. n = 22 per group. (C) Representative hematoxylin and eosin images of pancreas in ARG-induced SAP model. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours. n = 16–18 per group. (E) Histologic score of pancreatic injury and cell death area of pancreas. n = 11–16 per group. Data were expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PAD4 knockout alleviates SAP and inhibits ADAMTS13 activity by citrullination. Details for experimental SAP induction and severity assessment are described in Materials and Methods section. Mice (WT and Pad4−/−) were harvested at 24 hours after the first CER/PBS injection. (A) Representative hematoxylin and eosin images of pancreas and lungs in CER+LPS–induced SAP model. Scale bar, 200 or 50 μm. n = 6 per group. (B) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 6 per group. (C) Histologic scores of lung injuries. n = 6 per group. (D) Immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 50 μm. n = 6 per group. (E) Western blotting of PAD4 in pancreatic tissue. n = 6 per group. (F) Plasma ADAMTS13 activity assessed by its ability to cleave FRETS-VWF73. Activity in vehicle-treated samples was set as 100% and used as the reference for normalization. n = 6 per group. (G) The distribution of large molecular–size VWF polymers in plasma. n = 6 per group. (H) Citrullinated ADAMTS13 detected by immunoprecipitation. n = 6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. PAD4 knockout (Pad4−/−) mice exhibits increased severity of ARG-induced SAP. (A) Study schematic: WT or Pad4−/− mice were injected with ARG to induce SAP. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Pad4−/−) were harvested at 72 hours after the first ARG injection. (B) Kaplan–Meier curve showing survival rates. n = 22 per group. (C) Representative hematoxylin and eosin images of pancreas in ARG-induced SAP model. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours. n = 16–18 per group. (E) Histologic score of pancreatic injury and cell death area of pancreas. n = 11–16 per group. Data were expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Deficiency Abrogates the Protective Effect of Peptidylarginine Deiminase Type IV Inhibition To determine whether PAD4 inhibition mitigates AP severity via regulation of ADAMTS13, Cl-amidine was administered to Adamts13−/− mice. Although Cl-amidine effectively reduced PAD4 expression and NETs formation, it failed to further reduce disease severity in Adamts13−/− mice compared with untreated controls. These findings indicate that the protective effect of PAD4 inhibition in SAP is largely dependent on the presence of functional ADAMTS13 (Figure 13A–E). Taken together, the roles of PAD4 and the ADAMTS13/VWF imbalance in AP are summarized in Figure 13F.Figure 13ADAMTS13 deficiency abrogates the protective effect of PAD4 inhibition. (A) Study schematic: Mice received single intraperitoneal injection of Cl-amidine (5 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Adamts13−/−) were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Representative immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 5–6 per group. (E) Levels of relative positive area of PAD4 and MPO and CitH3. n = 5–6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. (F) Study summary: In this study, we demonstrated that an early imbalance in the VWF–ADAMTS13 axis, characterized by reduced ADAMTS13 activity and increased levels of large molecular–weight VWF polymers, occurs in both patients with AP and experimental AP models. This imbalance is accompanied by PAD4 activation and proinflammatory NET formation. ADAMTS13 deficiency exacerbated pancreatic microthrombotic formation, thereby promoting pancreatic necrosis and distant organ injury, whereas administration of recombinant ADAMTS13 conferred protective effects. Moreover, PAD4 activation aggravated AP primarily through the inhibition of ADAMTS13 activity. Mechanistically, PAD4 suppressed ADAMTS13 activity both in vitro and in vivo, with citrullination identified as a potential mechanism underlying PAD4-mediated ADAMTS13 inactivation. ADAMTS13 deficiency abrogates the protective effect of PAD4 inhibition. (A) Study schematic: Mice received single intraperitoneal injection of Cl-amidine (5 mg/kg) immediately after AP induction. Details for experimental SAP induction and severity assessment are described in the Materials and Methods section. Mice (WT and Adamts13−/−) were harvested at 24 hours after the first CER/PBS injection. (B) Representative hematoxylin and eosin images. Scale bar, 200 or 50 μm. (C) Representative immunohistochemistry staining of PAD4 and immunofluorescence staining of MPO and CitH3 in pancreatic tissue. Scale bar, 200 or 50 μm. (D) Plasma amylase levels at 12 hours, histologic scores of pancreatic injuries, and cell death area of pancreas. n = 5–6 per group. (E) Levels of relative positive area of PAD4 and MPO and CitH3. n = 5–6 per group. Data are expressed as mean ± standard error of the mean. ns, nonsignificant, ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. (F) Study summary: In this study, we demonstrated that an early imbalance in the VWF–ADAMTS13 axis, characterized by reduced ADAMTS13 activity and increased levels of large molecular–weight VWF polymers, occurs in both patients with AP and experimental AP models. This imbalance is accompanied by PAD4 activation and proinflammatory NET formation. ADAMTS13 deficiency exacerbated pancreatic microthrombotic formation, thereby promoting pancreatic necrosis and distant organ injury, whereas administration of recombinant ADAMTS13 conferred protective effects. Moreover, PAD4 activation aggravated AP primarily through the inhibition of ADAMTS13 activity. Mechanistically, PAD4 suppressed ADAMTS13 activity both in vitro and in vivo, with citrullination identified as a potential mechanism underlying PAD4-mediated ADAMTS13 inactivation. Discussion To our knowledge, this is the most comprehensive study to date investigating the VWF–ADAMTS13 imbalance in experimental AP, and the first to suggest a mechanistic link between proinflammatory NETs formation and prothrombotic VWF–ADAMTS13 imbalance in AP. We found that reduced ADAMTS13 activity and elevated VWF levels in plasma were present in both patients with AP and mouse models. RhADAMTS13 alleviated thrombosis formation and disease severity, whereas Adamts13 deficiency exacerbated SAP. Plasma PAD4 levels inversely correlated with ADAMTS13 activity. PAD4 inhibited ADAMTS13 activity both in vitro and in vivo, whereas genetic or pharmacologic PAD4 inhibition restored ADAMTS13 activity and attenuated SAP. Notably, PAD4 inhibition failed to confer a protective effect in Adamts13−/− mice, confirming ADAMTS13 as a critical mediator in PAD4-driven pathogenesis of AP. We observed a consistent VWF–ADAMTS13 imbalance in patients with AP, aligning with previous studies.7,18 The protective effects of rhADAMTS13 in reducing thrombosis and disease severity highlight its therapeutic potential in AP. Approved by the United States Food and Drug Administration in 2023 for congenital thrombotic thrombocytopenic purpura, rhADAMTS13 has also shown anti-inflammatory and antithrombotic benefits in preclinical models of inflammatory conditions such as inflammatory bowel disease, sepsis, rheumatoid arthritis, and liver failure.19 Our findings support further clinical evaluation of rhADAMTS13 for AP treatment. Although reduced ADAMTS13 activity is frequently reported in secondary thrombotic microangiopathies (eg, disseminated intravascular coagulation, stroke, and deep vein thrombosis), its underlying cause remains unclear.10, 11, 12 Prior studies suggested proteolytic inactivation by neutrophil elastase or plasmin in vitro,20,21 yet this mechanism appears limited in vivo.22 It has been reported that both ADAMTS13 and NETs bind VWF, enabling potential interaction between ADAMTS13 and certain NETs components. Our results demonstrate that PAD4 can citrullinate ADAMTS13 both in vitro and in vivo, revealing a novel mechanism of inflammation-driven ADAMTS13 inactivation. This finding bridges thrombo-inflammation and ADAMTS13 deficiency, offering new therapeutic targets within the VWF–ADAMTS13 axis. Although previous studies have reported that the deficiency of PAD4 or treatment with PAD inhibitors could reduce disease severity in mice AP models, the impact of extracellular PAD4 on the microcirculation of pancreas has not been addressed.23,24 PAD4, known for its involvement in NETs formation and the regulation of inflammatory responses, holds potential to citrullinate other protein in plasma. As a member of the PAD enzyme family, PAD4 has the ability to citrullinate some specific protein substrates, many of which play important roles in cellular processes such as gene regulation, cellular differentiation, and inflammation.25 Dysregulated PAD4 activity and abnormal levels of protein citrullination have been linked to various inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, Alzheimer and sepsis.26, 27, 28, 29 Interestingly, lots of arginine residues have been found within ADAMTS13, involving its metalloprotease domain, rendering citrullination of ADAMTS13 possible.30 In this study, we first reported citrullinated ADAMTS13 in AP mice, with PAD4 being the primary culprit, unveiling the key role of the PAD4–ADAMTS13 pathway in AP. Sorvillo et al also found this PAD4–ADAMTS13 interaction phenomenon among patients with sepsis or chronic comorbidities.17 However, they were unable to determine the crucial role of the PAD4–ADAMTS13 pathway because other plasma proteins may be citrullinated and contribute to the reported prothrombotic action of PAD4 in plasma. By employing Adamts13 knockout mice, our findings provide compelling evidence that the protective effects of PAD4 inhibition are largely abolished in the absence of ADAMTS13, identifying it as a primary downstream effector in the context of AP. Nevertheless, we acknowledge that PAD4 is a pleiotropic enzyme; beyond ADAMTS13 suppression, it likely modulates disease severity through additional pathways, such as the induction of NETs23,31 and the citrullination of inflammatory cytokines or coagulation molecules.25,32,33 Although the PAD4–ADAMTS13 axis appears to be a dominant mechanism in our model, these parallel PAD4-dependent processes may further amplify the thrombo-inflammatory cascade. Consequently, therapies aimed at restoring or enhancing ADAMTS13 activity, potentially in combination with PAD4 inhibition, may hold significant promise for treating AP and other thrombo-inflammatory disorders. There are limitations to our study. It is important to note that the clinical study is limited by a modest sample size. In addition, the association between ADAMTS13 activity and NETs components did not reveal the direct mechanism. Therefore, these findings should be considered as hypothesis-generating and interpreted with caution. Lastly, although our time-course experiments (0–3 hours postinduction) demonstrate a consistent protective effect of PAD4 inhibition, we acknowledge that immediate or early intervention in murine models primarily establishes biological plausibility. The clinical translation of these findings, particularly the determination of an optimal therapeutic window in patients with AP, remains to be established in future clinical trials. Conclusions In summary, our findings highlight the crucial role of VWF/ADAMTS13 imbalance and NETs/PAD4 in linking thrombosis, pancreatic necrosis, and systemic inflammation in AP. Therapeutic approaches focused on preserving ADAMTS13 activity or inhibiting PAD4 warrant further clinical investigation in AP. Materials and Methods Ethics The Principles of Laboratory Animal Care (National Institutes of Health publication no. 85Y23, revised 1996) was followed, and the Experimental Animal Ethics Committee approved all experimental protocols of Jinling Hospital, Medical School of Nanjing University (No. 2018GKJDWLS-03-156). A prospective, observational cohort study was conducted to investigate the dynamic relationship between NETs formation and ADAMTS13 activity. Blood samples were collected from patients admitted within 48 hours of symptom onset. The study was approved by the Ethics Committee of Jinling Hospital (Ethical ID: 2020DZGZRZX-061) and complied with the Declaration of Helsinki. The study protocol was registered on the Chinese Clinical Trials Registry (ChiCTR2200057233) before enrollment commenced. Written informed consent was obtained from all the participants or their next of kin prior to enrollment. Patient and Public Involvement Statement Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research. Human Blood Sample Collection Patients meeting with the following criteria were included: (1) aged 18 to 80 years; (2) diagnosed with AP per the Revised Atlanta Classification34; and (3) admitted within 48 hours of symptom onset. Patients with disseminated intravascular coagulation at admission, recurrent AP, in pregnancy, or having received any surgical intervention before admission were excluded. The relevant demographic and clinical data of participants were recorded. Blood samples were collected daily for the first 3 days, processed by centrifugation, and stored at −80 °C for analysis. We assumed that the prevalence of pancreatic necrosis >30% would be approximately 40%. A sample size of 30 would provide 80% power to detect a mean difference of 0.2 (standard deviation [SD], 0.2) in ADAMTS13 activity. Animals Eight- to ten-week-old male WT and genetic knockout mice (Pad4−/− and Adamts13−/−) were obtained from Model Animal Research Center of Nanjing University. All mice were of C57BL/6 background. All mice were housed under specific pathogen–free conditions in an air-conditioned animal facility at 24 °C on a 12-hour light/dark cycle. Animals were allowed access to water and standard laboratory chow ad libitum. Sex as a Biological Variable Our study exclusively examined male mice. It is unknown whether the findings are relevant for female mice. Induction of Acute Pancreatitis in Mice and Interventions SAP was induced in mice using 2 models: (1) CER+ LPS model: CER (200 μg/kg) was intraperitoneally injected 7 times at hourly intervals, followed by 1 dose of LPS (5 mg/kg) 1 hour after the last injection of CER.35,36 (2) ARG model: ARG (8%, 3.3 g/kg, pH 7.4) was intraperitoneally administered 3 times at hourly intervals to induce excessive amino acid–induced AP.36,37 Controls received volume-matched phosphate-buffered saline (PBS; pH 7.4). Interventions included rhADAMTS13 (10, 50, or 250 μg/kg), Cl-amidine (5 mg/kg) or rhPAD4 (10 mg/kg), administered intraperitoneally immediately after AP induction. PBS served as the vehicle control. In addition, to systematically evaluate the impact of intervention timing, we specifically compared drug administration at 0, 1, and 3 hours postinduction. Blood samples were collected from the tail vein of mice at 12 hours after the first CER/ARG injection. Mice were euthanized and humanely killed at 24 hours (CER model) or 72 hours (ARG model) after the first injection. Pancreatic and lung tissues were harvested for histologic examination, and the remaining tissues were snap-frozen at −80 °C for further analysis. All the reagents and antibodies used in this study are provided in Table 1.Table 1Key Resources TableReagent or resourceSource (location)IdentifierAntibodies Rabbit anti-ADAMTS13 antibodyAbcam (Cambridge, UK)Cat# ab71550 Polyclonal anti-VWF antibodyDAKO (Santa Clara, CA)Cat# a008229-2 Anti-fibrinogen antibodyAbcam (Cambridge, UK)Cat# ab189490 Goat anti-rabbit IgG HRP antibodiesSigma-Aldrich (St. Louis, MO)Cat# AP132 Anti-PAD4 antibodyAbcam (Cambridge, UK)Cat# ab214810 Goat anti-ADAMTS13 antibodyAbcam (Cambridge, UK)Cat# ab219407 Anti–pan-citrillineSigma-Aldrich (St. Louis, MO)Cat# MABN328 Anti-citrullinated H3Abcam (Cambridge, UK)Cat# ab5103 Anti-MPO antibodyAbcam (Cambridge, UK)Cat# ab208670 VWF mouse monoclonal antibodyProteintech (Chicago, IL)Cat# 66682 CD41 rabbit polyclonal antibodyProteintech (Chicago, IL)Cat# 24552Chemicals, peptides, and recombinant proteins CERSigma-Aldrich (St. Louis, MO)Cat# C9026 LPSSigma-Aldrich (St. Louis, MO)Cat# L2630 ArgSangon Biotech (Shanghai, China)Cat# A600205 RhADAMTS13 ProteinR&D Systems (Minneapolis, MN)Cat# 6156-AD-020 Cl-amidineCayman (Ann Arbor, MI)Cat# 10599 RhPAD4 proteinCayman (Ann Arbor, MI)Cat# 10500 FRETS-VWF73Peptide (Louisville, KY)Cat# 3224-S ADAMTS13 activity ELISA kit for humanTechnoclone Gmbh (Vienna, Australia)Cat# RU77B00.01 EPCR ELISA kit for humanCloud-Clone Corp (Wuhan, China)Cat# SEA022Hu EPCR ELISA kit for miceCloud-Clone Corp (Wuhan, China)Cat# SEA022Mu P-selectin ELISA kit for miceCloud-Clone Corp (Wuhan, China)Cat# SEA569Mu IL6 ELISA kit for miceFcmacs Biotech (Nanjing, China)Cat# ELM006 TNF-α ELISA kit for miceFcmacs Biotech (Nanjing, China)Cat# ELM028 VWF ELISA kit for humanCloud-Clone Corp (Wuhan, China)Cat# CEA833Hu Quant-iT PicoGreen dsDNA Assay kitInvitrogen (Carlsbad, CA)Cat# P11496 Peroxidase-labeled anti-DNA monoclonal antibody of the cell death ELISARoche (Basel, Switzerland)Cat# 11774425001 Plasma amylase kitBioTechnology & Science (Beijing, China)Cat# 100000060 Protein G agarose beadsCell Signaling Technology (Danfoss, MA)Cat# 37478S Protein L magnetic beadsInvitrogen (Carlsbad, CA)Cat# 88849Other GelBond FilmLonza (Basel, Switzerland)Cat# 53761ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; ARG, L-arginine; CER, caerulein; ELISA, enzyme-linked immunosorbent assay; EPCR, endothelial protein C receptor; HRP. horseradish peroxidase; IL6, interleukin6; LPS, lipopolysaccharide; MPO, myeloperoxidase; rh, recombinant human; TNF-α, tumor necrosis factor-α; VWF, von Willebrand factor. Table 1Key Resources TableReagent or resourceSource (location)IdentifierAntibodies Rabbit anti-ADAMTS13 antibodyAbcam (Cambridge, UK)Cat# ab71550 Polyclonal anti-VWF antibodyDAKO (Santa Clara, CA)Cat# a008229-2 Anti-fibrinogen antibodyAbcam (Cambridge, UK)Cat# ab189490 Goat anti-rabbit IgG HRP antibodiesSigma-Aldrich (St. Louis, MO)Cat# AP132 Anti-PAD4 antibodyAbcam (Cambridge, UK)Cat# ab214810 Goat anti-ADAMTS13 antibodyAbcam (Cambridge, UK)Cat# ab219407 Anti–pan-citrillineSigma-Aldrich (St. Louis, MO)Cat# MABN328 Anti-citrullinated H3Abcam (Cambridge, UK)Cat# ab5103 Anti-MPO antibodyAbcam (Cambridge, UK)Cat# ab208670 VWF mouse monoclonal antibodyProteintech (Chicago, IL)Cat# 66682 CD41 rabbit polyclonal antibodyProteintech (Chicago, IL)Cat# 24552Chemicals, peptides, and recombinant proteins CERSigma-Aldrich (St. Louis, MO)Cat# C9026 LPSSigma-Aldrich (St. Louis, MO)Cat# L2630 ArgSangon Biotech (Shanghai, China)Cat# A600205 RhADAMTS13 ProteinR&D Systems (Minneapolis, MN)Cat# 6156-AD-020 Cl-amidineCayman (Ann Arbor, MI)Cat# 10599 RhPAD4 proteinCayman (Ann Arbor, MI)Cat# 10500 FRETS-VWF73Peptide (Louisville, KY)Cat# 3224-S ADAMTS13 activity ELISA kit for humanTechnoclone Gmbh (Vienna, Australia)Cat# RU77B00.01 EPCR ELISA kit for humanCloud-Clone Corp (Wuhan, China)Cat# SEA022Hu EPCR ELISA kit for miceCloud-Clone Corp (Wuhan, China)Cat# SEA022Mu P-selectin ELISA kit for miceCloud-Clone Corp (Wuhan, China)Cat# SEA569Mu IL6 ELISA kit for miceFcmacs Biotech (Nanjing, China)Cat# ELM006 TNF-α ELISA kit for miceFcmacs Biotech (Nanjing, China)Cat# ELM028 VWF ELISA kit for humanCloud-Clone Corp (Wuhan, China)Cat# CEA833Hu Quant-iT PicoGreen dsDNA Assay kitInvitrogen (Carlsbad, CA)Cat# P11496 Peroxidase-labeled anti-DNA monoclonal antibody of the cell death ELISARoche (Basel, Switzerland)Cat# 11774425001 Plasma amylase kitBioTechnology & Science (Beijing, China)Cat# 100000060 Protein G agarose beadsCell Signaling Technology (Danfoss, MA)Cat# 37478S Protein L magnetic beadsInvitrogen (Carlsbad, CA)Cat# 88849Other GelBond FilmLonza (Basel, Switzerland)Cat# 53761ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; ARG, L-arginine; CER, caerulein; ELISA, enzyme-linked immunosorbent assay; EPCR, endothelial protein C receptor; HRP. horseradish peroxidase; IL6, interleukin6; LPS, lipopolysaccharide; MPO, myeloperoxidase; rh, recombinant human; TNF-α, tumor necrosis factor-α; VWF, von Willebrand factor. Key Resources Table ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; ARG, L-arginine; CER, caerulein; ELISA, enzyme-linked immunosorbent assay; EPCR, endothelial protein C receptor; HRP. horseradish peroxidase; IL6, interleukin6; LPS, lipopolysaccharide; MPO, myeloperoxidase; rh, recombinant human; TNF-α, tumor necrosis factor-α; VWF, von Willebrand factor. Plasma Biochemical Assays in Mice Mouse plasma amylase levels were measured using a commercial kit. The plasma levels of endothelial markers including EPCR, P-selectin, and inflammatory cytokines (interleukin6, tumor necrosis factor-α) were quantified by enzyme-linked immunosorbent assay (ELISA), following manufacturers’ protocols. A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 Activity Assay ADAMTS13 activity was assessed using the fluorescence-quenching substrate for ADAMTS13 (FRETS-VWF73) per manufacturer’s instructions. In brief, samples (1.3 nmol/L rhADAMTS13 or 1 μL plasma) were incubated with 2 μM FRETS-VWF73 substrate, and fluorescence was measured every 5 minutes for 1 hour using a Synergy Neo microplate reader (Biotek). The activity of rhADAMTS13 was calculated by analyzing the slope value of the linear phase of the fluorescence curve. The ADAMTS13 activity was normalized to pooled controls of healthy patients or mice. In Vitro Incubation Between Recombinant Human Peptidylarginine Deiminase Type IV and Recombinant Human A Disintegrin and Metalloproteinase With Thrombospondin Type 1 Motif, Member 13 RhADAMTS13 (0.5 μmol/L) was incubated with rhPAD4 (1 μmol/L) in citrullination buffer (50 mmol/L Tris-HCl, 4 mmol/L CaCl2, pH 7.6) at 37 °C for 180 minutes (final volume: 20 μL). For PAD4 inhibition, rhPAD4 was pre-treated with Cl-amidine (200 μmol/L) for 20 minutes at 37 °C before coincubation with rhADAMTS13. Assessment of von Willebrand Factor Multimeric Structures Briefly, VWF multimers were analyzed by 1.0% agarose gel electrophoresis under reducing conditions. Sample buffer (0.5 M Tris-HCl [pH 6.8], 0.5 M EDTA, 9 M Urea, 20% sodium dodecyl sulfate [SDS]) was used to dilute the plasma samples. Plasma samples (1:40 dilution, 10 μL) were loaded and electrophoresed at 90 V for 4 to 5 hours at 4 °C, then transferred overnight to GelBond Film. After blocking with 5% nonfat milk, membranes were incubated with polyclonal anti-VWF antibody (dilution 1:1000, 1.5 hours) followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG antibody (dilution 1:3000, 1 hour). Separate bands were visualized using the ECL Plus chemiluminescent system and analyzed using TL100 software (TotalLab) and FIJI software (Image-J; National Institutes of Health) for densitometry. Quantification of Neutrophil–Extracellular Traps cfDNA in mouse and human plasma was quantified using the Quant-iT PicoGreen dsDNA Assay kit per manufacturer’s protocol. CitH3–DNA complexes were measured by a modified-capture ELISA38: 96-well plates were coated overnight at 4 °C with anti-histone H3 antibody (5 μg/mL), blocked with 5% bovine serum albumin (2 hours), then incubated with 50 μL plasma samples and 50 μL peroxidase-labeled anti-DNA monoclonal antibody (2 hours, 300 rpm, room temperature). After washing, peroxidase substrate (ABTS, 100 μL) was added, and absorbance was read at 405 nm after 30 minutes. Values for soluble NETs formation were expressed as percent absorbance increase over controls. Plasma PAD4 levels were measured by ELISA following manufacturer instructions. Histopathologic Examination Paraffin-embedded pancreatic tissues were sectioned at 5 μm and stained with hematoxylin and eosin. Two pathologists independently scored injury severity—edema, inflammation, and necrosis—using light microscopy,39 resolving discrepancies by consensus. Immunohistochemistry Slides were incubated overnight at 4 °C in a humid chamber with anti-fibrinogen (1:2000) or anti-PAD4 (1:1000) antibodies, followed by goat anti-rabbit secondary antibody (1:3000) for 1 hour. Images were captured using a microscope (IX73; Olympus) and analyzed with FIJI software (Image-J; National Institutes of Health). Immunofluorescence Slices were blocked with 5% bovine serum albumin in PBS containing 0.05% Tween 20 (PBST) for 30 minutes, then incubated overnight at 4 °C with 4',6-diamidino-2-phenylindole (DAPI) (1:200), anti-citH3, anti-MPO, anti-platelet glycoprotein IIb (CD41), and anti-VWF antibodies (all 1:200 dilution). Alexa Fluor 488 (green)–conjugated secondary antibody was applied for 2 hours at room temperature in the dark. After washing, DAPI was used for nuclear staining. Excitation/emission wavelengths were 377/447 nm for the DAPI, 543/586 nm for the anti-citrullinated H3 and VWF antibodies, and 494/527 nm for the anti-MPO and anti-CD41 antibodies. Imaging was done using an Olympus IX71 inverted fluorescence microscope (Olympus). Western Blot Analysis Plasma samples were diluted 1:40 in loading buffer, pancreatic tissues were lysed in radio immunoprecipitation assay buffer, and then total proteins were extracted. Protein concentrations were determined by the bicinchoninic acid assay, and 30 μg protein per sample was denatured at 95 °C for 5 minutes. Samples were resolved on 10% SDS–polyacrylamide gel electrophoresis gels at 90 V for 2.5 hours (4 °C) and transferred to polyvinylidene fluoride membranes at 250 mA for 2 hours. Membranes were incubated overnight at 4 °C with primary antibodies against ADAMTS13 or PAD4 (both 1:3000 dilution), followed by HRP-conjugated goat anti-rabbit secondary antibody (1:5000 dilution) for 1 h. After tris-buffered saline with Tween-20‌ washes, all blots were developed by using the ECL Plus chemiluminescent system and analyzed with FIJI software (Image-J; National Institutes of Health). Coimmunoprecipitation Precleared samples were incubated overnight at 4 °C with polyclonal goat anti-ADAMTS13 or anti–pan-citrulline antibodies in PBST. Sepharose or L magnetic beads for IgM antibodies were added for 1 hour at room temperature. After washing with loading buffer, bound proteins were eluted by heating at 95 °C for 10 minutes. Supernatants were subjected to SDS-polyacrylamide gel electrophoresis and transferred onto PDVF membranes. Citrullination was detected using anti–pan-citrulline antibody (1 μg/mL in 5% milk, tris-buffered saline with Tween-20) with HRP-conjugated anti-mouse IgM and anti-rabbit IgG secondary antibodies. Molecular weight markers were included on all immunoblots to indicate protein size. Statistical Analysis Continuous variables were presented as mean ± standard deviation or mean ± standard error of the mean for normally distributed data or median (interquartile range) for non-normal data, whereas categorical variables were expressed as frequency (%). Normally distributed variables were analyzed using Student’s t test or analysis of variance; non-normally distributed variables using the Mann–Whitney U or Kruskal–Wallis test. Categorical variables were compared using Fisher’s exact test. Repeated-measures analysis of variance was performed for intergroup differences after confirming sphericity assumptions. ROC analyses were used to evaluate the predictive performance. Associations between NETs components and ADAMTS13 activity were evaluated using Pearson correlation with R2 values reported. Data were analyzed using GraphPad Prism software (version 6.0, GraphPad Software Inc) and IBM SPSS Statistics 22.0 (IBM Corporation). A 2-sided P < .05 was considered statistically significant.